187 related articles for article (PubMed ID: 26546218)
1. Structure-activity-relationship of amide and sulfonamide analogs of omarigliptin.
Chen P; Feng D; Qian X; Apgar J; Wilkening R; Kuethe JT; Gao YD; Scapin G; Cox J; Doss G; Eiermann G; He H; Li X; Lyons KA; Metzger J; Petrov A; Wu JK; Xu S; Weber AE; Yan Y; Roy RS; Biftu T
Bioorg Med Chem Lett; 2015 Dec; 25(24):5767-71. PubMed ID: 26546218
[TBL] [Abstract][Full Text] [Related]
2. Omarigliptin (MK-3102): a novel long-acting DPP-4 inhibitor for once-weekly treatment of type 2 diabetes.
Biftu T; Sinha-Roy R; Chen P; Qian X; Feng D; Kuethe JT; Scapin G; Gao YD; Yan Y; Krueger D; Bak A; Eiermann G; He J; Cox J; Hicks J; Lyons K; He H; Salituro G; Tong S; Patel S; Doss G; Petrov A; Wu J; Xu SS; Sewall C; Zhang X; Zhang B; Thornberry NA; Weber AE
J Med Chem; 2014 Apr; 57(8):3205-12. PubMed ID: 24660890
[TBL] [Abstract][Full Text] [Related]
3. Design, Synthesis, and Evaluation of a Series of Novel Super Long-Acting DPP-4 Inhibitors for the Treatment of Type 2 Diabetes.
Zhang C; Ye F; Wang J; He P; Lei M; Huang L; Huang A; Tang P; Lin H; Liao Y; Liang Y; Ni J; Yan P
J Med Chem; 2020 Jul; 63(13):7108-7126. PubMed ID: 32452679
[TBL] [Abstract][Full Text] [Related]
4. Novel tetrahydropyran analogs as dipeptidyl peptidase IV inhibitors: Profile of clinical candidate (2R,3S,5R)-2- (2,5-difluorophenyl)-5-(4,6-dihydropyrrolo [3,4-c]pyrazol-5-(1H)-yl)tetrahydro-2H-pyran-3-amine (23) [corrected].
Biftu T; Qian X; Chen P; Feng D; Scapin G; Gao YD; Cox J; Roy RS; Eiermann G; He H; Lyons K; Salituro G; Patel S; Petrov A; Xu F; Xu SS; Zhang B; Caldwell C; Wu JK; Lyons K; Weber AE
Bioorg Med Chem Lett; 2013 Oct; 23(19):5361-6. PubMed ID: 23972441
[TBL] [Abstract][Full Text] [Related]
5. Novel series of 3-amino-N-(4-aryl-1,1-dioxothian-4-yl)butanamides as potent and selective dipeptidyl peptidase IV inhibitors.
Nitta A; Fujii H; Sakami S; Satoh M; Nakaki J; Satoh S; Kumagai H; Kawai H
Bioorg Med Chem Lett; 2012 Dec; 22(23):7036-40. PubMed ID: 23072865
[TBL] [Abstract][Full Text] [Related]
6. Asymmetric Formal Synthesis of the Long-Acting DPP-4 Inhibitor Omarigliptin.
Peng F; Chen Y; Chen CY; Dormer PG; Kassim A; McLaughlin M; Reamer RA; Sherer EC; Song ZJ; Tan L; Tudge MT; Wan B; Chung JYL
J Org Chem; 2017 Sep; 82(17):9023-9029. PubMed ID: 28776371
[TBL] [Abstract][Full Text] [Related]
7. The discovery of novel 5,6,5- and 5,5,6-tricyclic pyrrolidines as potent and selective DPP-4 inhibitors.
Cox JM; Chu HD; Kuethe JT; Gao YD; Scapin G; Eiermann G; He H; Li X; Lyons KA; Metzger J; Petrov A; Wu JK; Xu S; Sinha-Roy R; Weber AE; Biftu T
Bioorg Med Chem Lett; 2016 Jun; 26(11):2622-6. PubMed ID: 27106708
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and biological evaluation of novel benzyl-substituted (S)-phenylalanine derivatives as potent dipeptidyl peptidase 4 inhibitors.
Liu Y; Si M; Tang L; Shangguan S; Wu H; Li J; Wu P; Ma X; Liu T; Hu Y
Bioorg Med Chem; 2013 Sep; 21(18):5679-87. PubMed ID: 23938053
[TBL] [Abstract][Full Text] [Related]
9. Synthesis, evaluation and molecular docking of thiazolopyrimidine derivatives as dipeptidyl peptidase IV inhibitors.
Sharma M; Gupta M; Singh D; Kumar M; Kaur P
Chem Biol Drug Des; 2012 Dec; 80(6):918-28. PubMed ID: 22943413
[TBL] [Abstract][Full Text] [Related]
10. Discovery of triazole-based uracil derivatives bearing amide moieties as novel dipeptidyl peptidase-IV inhibitors.
Deng X; Han L; Zhou J; Zhang H; Li Q
Bioorg Chem; 2017 Dec; 75():357-367. PubMed ID: 29096096
[TBL] [Abstract][Full Text] [Related]
11. Omarigliptin: first global approval.
Burness CB
Drugs; 2015 Nov; 75(16):1947-52. PubMed ID: 26507988
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and Pharmacodynamics of Omarigliptin, a Once-Weekly Dipeptidyl Peptidase-4 (DPP-4) Inhibitor, After Single and Multiple Doses in Healthy Subjects.
Krishna R; Addy C; Tatosian D; Glasgow XS; Gendrano Iii IN; Robberechts M; Haazen W; de Hoon JN; Depré M; Martucci A; Peng JZ; Johnson-Levonas AO; Wagner JA; Stoch SA
J Clin Pharmacol; 2016 Dec; 56(12):1528-1537. PubMed ID: 27225334
[TBL] [Abstract][Full Text] [Related]
13. Single and multiple dose pharmacokinetics and pharmacodynamics of omarigliptin, a novel, once-weekly dipeptidyl peptidase-4 inhibitor, in healthy Japanese men.
Tsuchiya S; Friedman E; Addy C; Wakana A; Tatosian D; Matsumoto Y; Suzuki H; Kauh E
J Diabetes Investig; 2017 Jan; 8(1):84-92. PubMed ID: 27182005
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, structure-activity relationships, and docking studies of 1-(γ-1,2,3-triazol substituted prolyl)-(S)-3,3-difluoropyrrolidines as a novel series of potent and selective dipeptidyl peptidase-4 inhibitors.
Zhang L; Su M; Li J; Ji X; Wang J; Li Z; Li J; Liu H
Chem Biol Drug Des; 2013 Feb; 81(2):198-207. PubMed ID: 22994702
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, and pharmacological evaluation of highly potent and selective dipeptidyl peptidase-4 inhibitors.
Jiang T; Zhou Y; Zhu J; Chen Z; Sun P; Zhang Q; Wang Z; Shao Q; Jiang X; Li B; Wang H; Zhu W; Shen J
Arch Pharm (Weinheim); 2015 Jun; 348(6):399-407. PubMed ID: 25871012
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and biological evaluation of all eight stereoisomers of DPP-IV inhibitor saxagliptin.
Dong J; Gong Y; Liu J; Chen X; Wen X; Sun H
Bioorg Med Chem; 2014 Feb; 22(4):1383-93. PubMed ID: 24457090
[TBL] [Abstract][Full Text] [Related]
17. Discovery and Rational Design of Natural-Product-Derived 2-Phenyl-3,4-dihydro-2H-benzo[f]chromen-3-amine Analogs as Novel and Potent Dipeptidyl Peptidase 4 (DPP-4) Inhibitors for the Treatment of Type 2 Diabetes.
Li S; Xu H; Cui S; Wu F; Zhang Y; Su M; Gong Y; Qiu S; Jiao Q; Qin C; Shan J; Zhang M; Wang J; Yin Q; Xu M; Liu X; Wang R; Zhu L; Li J; Xu Y; Jiang H; Zhao Z; Li J; Li H
J Med Chem; 2016 Jul; 59(14):6772-90. PubMed ID: 27396490
[TBL] [Abstract][Full Text] [Related]
18. Discovery of potent, selective, and orally bioavailable quinoline-based dipeptidyl peptidase IV inhibitors targeting Lys554.
Maezaki H; Banno Y; Miyamoto Y; Moritoh Y; Asakawa T; Kataoka O; Takeuchi K; Suzuki N; Ikedo K; Kosaka T; Sasaki M; Tsubotani S; Tani A; Funami M; Yamamoto Y; Tawada M; Aertgeerts K; Yano J; Oi S
Bioorg Med Chem; 2011 Aug; 19(15):4482-98. PubMed ID: 21741847
[TBL] [Abstract][Full Text] [Related]
19. Synthesis, Biological Evaluation, and Molecular Docking of (R)-2-((8-(3-aminopiperidin-1-yl)-3-methyl-7-(3-methylbut-2-en-1-yl)-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-1-yl)methyl)benzonitrile as Dipeptidyl Peptidase IV Inhibitors.
Ran Y; Pei H; Shao M; Chen L
Chem Biol Drug Des; 2016 Feb; 87(2):290-5. PubMed ID: 26426933
[TBL] [Abstract][Full Text] [Related]
20. Discovery and preclinical profile of teneligliptin (3-[(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl]thiazolidine): a highly potent, selective, long-lasting and orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
Yoshida T; Akahoshi F; Sakashita H; Kitajima H; Nakamura M; Sonda S; Takeuchi M; Tanaka Y; Ueda N; Sekiguchi S; Ishige T; Shima K; Nabeno M; Abe Y; Anabuki J; Soejima A; Yoshida K; Takashina Y; Ishii S; Kiuchi S; Fukuda S; Tsutsumiuchi R; Kosaka K; Murozono T; Nakamaru Y; Utsumi H; Masutomi N; Kishida H; Miyaguchi I; Hayashi Y
Bioorg Med Chem; 2012 Oct; 20(19):5705-19. PubMed ID: 22959556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
